A Phase 3 interventional study of Aroxybutynin and Atomoxetine in OSA, sponsored by Apnimed. Enrolling by invitation at 99 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by Apnimed · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Sleep Apnea, Obstructive by Apnimed — 1 open to participants now, 1 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Apnimed.
Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, this one has the largest planned enrollment, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 13th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →1 of the 13 studies in Sleep Apnea, Obstructive by Apnimed is open now, in 2 countries.
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 3
First in 2019; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,280 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 60 across the 13 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Apnimed is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Open Label AD109
Drug: Aroxybutynin and Atomoxetine
Drug page: AtomoxetineStudies of AtomoxetineAtomoxetine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Fixed Dose Combination
Also known as: AD109
Number of Participants With Adverse Events (AES) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. An SAE was an AE during any study phase that fulfills one or more of the following criteria: results in death, life threatening (The term 'life-threatening' in the definition of 'serious' refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity.
Time frame: through study completion, an average of 1 year
Number of Participants With Vital Signs Abnormalities
Vital signs that are planned to be assessed include parameters such as weight,heart rate and systolic and diastolic blood pressure.
Time frame: through study completion, an average of 1 year
Number of Participants With Concomitant Therapy (Medication or Devices)
Concomitant therapy with devices (i.e., CPAP) and concomitant medications are other prescription medications, over-the-counter (OTC) drugs or dietary supplements that a study participant takes in addition to the drug under investigation.
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jun 2026, 23 months after the start.
Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's planned 23 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atomoxetine
Apnimed